PPARgamma ligands attenuate mesangial contractile dysfunction in high glucose.
D000199:Actins / Q000235:genetics; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D002478:Cells, Cultured; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D016373:DNA, Antisense / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005419:Flavonoids / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects; D005920:Glomerular Mesangium / Q000166:cytology / Q000187:drug effects / Q000503:physiopathology*; D005947:Glucose / Q000494:pharmacology*; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D008024:Ligands; D000077205:Pioglitazone; D015230:Prostaglandin D2 / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics*; D045162:Thiazolidinediones / Q000494:pharmacology; D014157:Transcription Factors / Q000235:genetics*; D014662:Vasoconstrictor Agents / Q000494:pharmacology
C477819:15-deoxyprostaglandin J2; D000199:Actins; D016861:Cyclooxygenase Inhibitors; D016373:DNA, Antisense; D004791:Enzyme Inhibitors; D005419:Flavonoids; D007004:Hypoglycemic Agents; D008024:Ligands; D018160:Receptors, Cytoplasmic and Nuclear; D045162:Thiazolidinediones; D014157:Transcription Factors; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D005947:Glucose; D001241:Aspirin; D015230:Prostaglandin D2; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; D000077205:Pioglitazone; D007213:Indomethacin